In The Pipeline
The following drugs are still in clinical trials:
- The Food and Drug Administration’s arthritis advisory committee has unanimously recommended approval of Immunex’s Enbrel (etanercept) for use to delay radiographic progression of joint damage in patients with early rheumatoid arthritis and voted in favor of approval of Enbrel for use to improve signs and symptoms of patients with early stage disease.
- Genelabs Technologies Inc. reports statistically significant results from its phase III clinical trial of GL701 (prasterone, dehydroepiandrosterone) in treating systemic lupus erythematosus (SLE). Patients treated with GL701 had a significantly greater rate of response than those receiving placebo. Response to treatment was defined as improvement or stabilization of SLE disease activity and symptoms.